| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA915: Pegunigalsidase alfa for treating Fabry disease |
|
Medicine details |
|
| Medicine name | pegunigalsidase alfa (Elfabrio®) |
| Formulation | intravenous infusion |
| Reference number | 3683 |
| Indication | Long-term enzyme replacement therapy in adult patients with confirmed diagnosis of Fabry disease (deficiency of alpha galactosidase). |
| Company | Chiesi Limited |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/08/2023 |
| NICE guidance | |